The near-term test is whether reform meets the review's originally stated objective of modernising and accelerating access to new medicines and other health technologies. That outcome cannot be separated from the institutional response. Can any beneficial reforms hold? The United Kingdom offers a timely example of the risks. …
The live lesson from the UK on who holds the levers and how they use them
September 3, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Blood test for eight cancers arrives in Australia, but misses almost half of them
September 23, 2026 - -
Prescient raises $6 million to carry cancer drug PTX-100 past a key dosing decision
September 23, 2026 - - Australian Biotech -
Seven Australian startups share $15.6 million to take on dementia
September 23, 2026 - - Australian Biotech -
Dimerix draws $17 million from loan facility to fund kidney drug trials to completion
September 23, 2026 - - Australian Biotech -
Actinogen's Alzheimer's pill nears its moment of truth as final trial patient is seen
September 23, 2026 - - Australian Biotech -
Patrys doses first volunteers in trial of intravenous quetiapine for delirium
September 23, 2026 - - Australian Biotech -
Lilly goes direct with a patient platform for its non-PBS medicines
September 23, 2026 - - Latest News